The complexity of maternal immunisation schedules has historically presented a barrier to optimal vaccine uptake, leaving pregnant individuals and their neonates vulnerable to preventable infectious diseases. The American College of Obstetricians and Gynecologists (ACOG) has now issued a simplified maternal vaccine schedule, aiming to clarify recommendations and enhance adherence among clinicians and patients.
Maternal immunisation is a critical public health strategy, protecting both the pregnant individual and the neonate through passive antibody transfer. Despite established guidelines, vaccine uptake during pregnancy for diseases such as influenza, tetanus, diphtheria, acellular pertussis (Tdap), and COVID-19 has remained suboptimal. For instance, influenza vaccine coverage during pregnancy has consistently been around 50%, and Tdap coverage approximately 55%, according to CDC data.1 This under-immunisation contributes to preventable maternal and infant morbidity and mortality. The previous ACOG recommendations, while comprehensive, were distributed across multiple documents, potentially complicating their implementation in busy clinical settings. The objective of the new consolidated schedule is to provide a clear, concise, and actionable framework for clinicians.
The Simplified ACOG Maternal Vaccine Schedule
The updated ACOG guidance consolidates recommendations for routinely recommended vaccines during pregnancy into a single, accessible schedule. The primary vaccines emphasised are influenza, Tdap, and COVID-19. For influenza, the recommendation remains for administration during any trimester of pregnancy, ideally upon vaccine availability in the autumn.2 This aligns with the understanding that influenza infection during pregnancy is associated with increased risks of severe illness, hospitalisation, and adverse pregnancy outcomes, including preterm birth.3
The Tdap vaccine is recommended during each pregnancy, specifically between 27 and 36 weeks' gestation, irrespective of prior vaccination history.2 This timing is crucial for optimising the transfer of pertussis antibodies to the neonate, providing protection against whooping cough during the vulnerable first months of life before the infant can receive their primary immunisation series. Pertussis remains a significant cause of infant mortality globally.4
For COVID-19, ACOG reiterates the recommendation for vaccination and booster doses for pregnant and lactating individuals, consistent with CDC guidelines.2 Evidence indicates that pregnant individuals are at increased risk for severe COVID-19 outcomes, including intensive care unit admission, mechanical ventilation, and death, compared to non-pregnant individuals.5 Vaccination has been shown to reduce these risks and offers protection to the neonate.6
The simplified schedule also addresses other vaccines, such as measles, mumps, and rubella (MMR), and varicella, which are contraindicated during pregnancy but recommended postpartum for non-immune individuals.2 Additionally, it provides guidance on vaccines that may be indicated in specific circumstances, such as hepatitis B, hepatitis A, and meningococcal vaccines, based on individual risk factors or travel. The consolidation aims to reduce the cognitive load on clinicians, facilitating easier recall and application of recommendations during prenatal visits. This approach seeks to standardise practice and improve patient counselling regarding vaccine safety and efficacy during pregnancy. The guidance does not introduce new vaccines but rather streamlines the presentation of existing, evidence-based recommendations.
The ACOG's move to simplify the maternal vaccine schedule is a pragmatic response to persistent under-immunisation rates in pregnant populations. While the evidence for vaccinating against influenza, Tdap, and COVID-19 during pregnancy is robust, the fragmented nature of previous guidelines likely contributed to clinician confusion and suboptimal patient uptake. This consolidation should, in theory, reduce the administrative burden on general practitioners and obstetricians, making it easier to integrate vaccine discussions and administration into routine prenatal care. The emphasis on a clear, single schedule is a tacit acknowledgement that complexity is a barrier to compliance, even when the clinical benefits are substantial.
For patients, this streamlined approach means clearer communication from their healthcare providers. The goal is to empower pregnant individuals to make informed decisions without being overwhelmed by disparate recommendations. Improved vaccine uptake directly translates to reduced maternal morbidity and, crucially, enhanced passive immunity for neonates, offering a vital shield against severe infections in their most vulnerable period. This is particularly pertinent for pertussis, where infant mortality remains a concern, and for influenza and COVID-19, which pose significant risks during pregnancy.
From an industry perspective, this simplification reinforces the established market for these vaccines. It underscores the ongoing need for effective public health campaigns to support guideline implementation, rather than relying solely on clinicians to navigate complex information. Pharmaceutical companies producing these vaccines will likely see a more consistent demand as adherence to the simplified schedule improves. The challenge now lies in ensuring that this simplified guidance translates into tangible increases in vaccination rates, moving beyond mere recommendation to widespread clinical practice.
- The Pivot ACOG has consolidated its maternal immunisation guidelines into a single, simplified schedule.
- The Data The updated guidance aims to improve vaccine uptake, which has historically been suboptimal for influenza (approximately 50%) and Tdap (approximately 55%) during pregnancy.
- The Action Clinicians should integrate the simplified ACOG schedule into routine prenatal care, focusing on influenza, Tdap, and COVID-19 vaccines.
ART-2026-284
Cite This Article
Team TLSFE. Acog simplifies maternal immunisation schedule for gps. The Life Science Feed. Updated June 11, 2026. Accessed June 11, 2026. https://thelifesciencefeed.com/obstetrics-and-gyn/pregnancy-complications/guidelines/acog-simplifies-maternal-immunisation-schedule-for-gps.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
1. Centers for Disease Control and Prevention. Flu and Tdap Vaccination Coverage Among Pregnant Women - United States, 2022-23 Influenza Season. MMWR Morb Mortal Wkly Rep. 2023;72(38):1035-1040.
2. American College of Obstetricians and Gynecologists. Immunization and Pregnancy: ACOG Committee Opinion No. 827. Obstet Gynecol. 2021;137(6):e190-e202.
3. Rasmussen SA, et al. Pandemic influenza and pregnancy: planning for the next pandemic. Am J Obstet Gynecol. 2008;198(1):14-25.
4. World Health Organization. Pertussis vaccines: WHO position paper – August 2015. Wkly Epidemiol Rec. 2015;90(35):433-458.
5. Zambrano LD, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(44):1641-1647.
6. Halasa NB, et al. Maternal Vaccination and Risk of Hospitalization Due to COVID-19 in Infants. N Engl J Med. 2022;386(19):1815-1826.
